You remember Martin Shkreli. He rocketed to notoriety three years ago when the company he ran, Turing Pharmaceuticals, bought an old anti-infective drug used by AIDS patients and quickly boosted the price of a tablet to $750 from $13.55. He was widely derided by the pharmaceutical industry as an outlier, although many other companies have regularly trafficked in such maneuvers.
A new analysis, however, suggests these moves are even more common than imagined.
A group of researchers examined a few dozen older drugs that no longer had patent protection but had changed hands, and they found the median price more than doubled after acquisition.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
